放射性药物治疗在寡转移性疾病管理中的潜在贡献
本文综述了寡转移性疾病(≤5个病灶)的认识进展,先进分子影像如前列腺特异性膜抗原PET可早期检出寡复发,转移导向治疗(MDT)是替代或延迟系统治疗的探索方向,但常不能持久治愈且多部位新发进展仍是顾虑;同时α发射和β发射放射性配体治疗(RLT)在高瘤负荷晚期转移性去势抵抗性前列腺癌中显示总生存获益,提示将RLT与MDT整合用于寡复发疾病可能减少进展包括多转移性进展。
要点
- 寡转移性疾病定义为存在5个或更少病灶。
- 前列腺特异性膜抗原PET等先进分子影像技术可更早检出寡复发。
- MDT常不能提供持久治愈,多部位新发进展仍是顾虑。
核心结论
- RLT在晚期疾病中的成功提示在疾病谱更早期使用可能有效,将RLT与MDT整合可能减少寡复发疾病中的进展包括多转移性进展。
主要发现
- 先进分子影像技术如前列腺特异性膜抗原PET提高了早期检出寡复发的能力。
- MDT常不能提供持久治愈,进展尤其是多部位新发进展仍是顾虑。
- α发射和β发射RLT在高瘤负荷晚期转移性去势抵抗性前列腺癌中显示总生存获益。
关键数值与推荐
- 寡转移性疾病特征为存在5个或更少病灶。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is a growing understanding of the oligometastatic disease state, characterized by the presence of 5 or fewer lesions. Advanced molecular imaging techniques, such as prostate-specific membrane antigen PET, refines the ability to detect oligometastatic recurrences (oligorecurrences) early. These developments have led to the exploration of metastasis-directed therapy (MDT) in oligorecurrent disease as an alternative to or as a means of delaying systemic therapy. Unfortunately, MDT often does not provide a durable cure, and progression-particularly progression in multiple new areas-remains a concern. Simultaneously, developments in radioligand therapy (RLT) have led to studies showing overall survival benefits with α-emitting and β-emitting RLT in advanced, high-volume, metastatic castration-resistant prostate cancer. The success of RLT in late-stage disease suggests that earlier use in the disease spectrum may be impactful. Specifically, integration of RLT with MDT might reduce progression, including polymetastatic progression, in the setting of oligorecurrent disease.
引用
- Kishan AU, Siva S, Hofman MS, et al. The Potential Contribution of Radiopharmaceutical Therapies in Managing Oligometastatic Disease. J Nucl Med. 2024. PMID: 38360048. doi:10.2967/jnumed.123.266772
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。